News

Novo Nordisk cautioned on Wednesday that it expects continued competition this year from copycat versions of its Wegovy ...
The pharmaceutical company's quarterly sales of its blockbuster Wegovy drug surged by two-thirds, despite many Americans ...
Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, after a major profit ...
Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...
Second-quarter sales of the blockbuster drug soared 67% on year, despite millions of U.S. patients using generic unbranded ...
Pedersen LONDON/COPENHAGEN (Reuters) -Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster ...
Novo Nordisk has announced the filing of 14 new lawsuits against the sale of unapproved compounded drugs claiming to contain ...
Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.
Danish diabetes and obesity giant Novo Nordisk has announced the filing of 14 new lawsuits to safeguard patients from unsafe ...
Novo Nordisk's already depressed share price has fallen again this morning, despite reporting an 18% increase in sales in the ...
Novo Nordisk (NVO) said Wednesday it will cut costs as it faces increasing competition from Eli Lilly (LLY) and generic ...
Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...